his.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Dynamics of three-dimensional telomere profiles of circulating tumor cells in patients with high-risk prostate cancer who are under going androgen deprivation and radiation therapies
Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Canada / Department of Human Anatomy and Cell Sciences, University of Manitoba, Winnipeg, Canada.
Department of Human Anatomy and Cell Sciences, University of Manitoba, Winnipeg, Canada / Medical Microbiology and Infectious Diseases, Department of Oncology, University of Calgary, Calgary, Alberta, Canada.
University of Skövde. Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Canada / Department of Clinical Genetics, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Canada.
Show others and affiliations
2017 (English)In: Urologic Oncology, ISSN 1078-1439, E-ISSN 1873-2496, Vol. 35, no 3, 112.e1-112.e11 p.Article in journal (Refereed) Published
Abstract [en]

Introduction: Accurate assessment and monitoring of the therapeutic efficacy of locally advanced prostate cancer remains a major clinical challenge. Contrary to prostate biopsies, circulating tumor cells (CTCs) are a cellular source repeatedly obtainable by blood sampling and could serve as a surrogate marker for treatment efficacy. In this study, we used size-based filtration to isolate and enumerate CTCs from the blood of 20 patients with high-risk (any one of cT3, Gleason 810, or prostate-specific antigen>20 ng/ml), nonmetastatic, and treatment-naive prostate cancer before and after androgen deprivation therapy (ADT) and radiation therapy (RT). Materials and methods: We performed 3D telomere-specific quantitative fluorescence in situ hybridization on isolated CTCs to determine 3D telomere profiles for each patient before and throughout the course of both ADT and RT. Results: Based on the distinct 3D telomere signatures of CTC before treatment, patients were divided into 3 groups. ADT and RT resulted in distinct changes in 3D telomere signatures of CTCs, which were unique for each of the 3 patient groups. Conclusion: The ability of 3D telomere analysis of CTCs to identify disease heterogeneity among a clinically homogeneous group of patients, which reveals differences in therapeutic responses, provides a new opportunity for better treatment monitoring and management of patients with high-risk prostate cancer. 

Place, publisher, year, edition, pages
2017. Vol. 35, no 3, 112.e1-112.e11 p.
Keyword [en]
High-risk prostate cancer, Telomeres, Circulating tumor cells, Biomarkers
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:his:diva-13794DOI: 10.1016/j.urolonc.2016.10.018ISI: 000401092000007Scopus ID: 2-s2.0-85008154395OAI: oai:DiVA.org:his-13794DiVA: diva2:1112415
Available from: 2017-06-20 Created: 2017-06-20 Last updated: 2017-06-29

Open Access in DiVA

No full text

Other links

Publisher's full textScopus
By organisation
University of Skövde
In the same journal
Urologic Oncology
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 22 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf